Any feedback?
Information on EC 5.3.99.2 - Prostaglandin-D synthase
for references in articles please use BRENDA:EC5.3.99.2Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
5.3.99.2 Prostaglandin-D synthaseIUBMB Comments
Brings about the opening of the epidioxy bridge. Some enzymes require glutathione.
Specify your search results
Word Map
- 5.3.99.2
-
cerebrospinal
-
arachidonic
- cox-2
- csf
-
cyclooxygenase
-
prostanoids
-
lipocalins
- indomethacin
- creatinine
- cystatin
-
mast
- sleep
-
glomerular
-
seminal
-
allergic
- leptomeninges
- aspirin
-
eicosanoids
-
thromboxane
-
leukotriene
-
nonsteroidal
- plexus
-
nsaid
- medicine
- synthase-1
-
subarachnoidal
-
1.14.99.1
-
ventrolateral
-
pgf2alpha
- transthyretin
-
preoptic
- rhinorrhea
-
endoperoxide
-
fistula
-
sleep-promoting
-
nephelometric
- beta2-microglobulin
- pghs-1
-
arachnoid
-
hydroperoxidase
-
sleep-wake
- analysis
- synthesis
- nutrition
The enzyme appears in viruses and cellular organisms
Reaction Schemes
Synonyms
l-pgds, prostaglandin synthase, beta-trace protein, ptgds, h-pgds, pgd synthase, prostaglandin d synthase, hpgds, lipocalin-type prostaglandin d synthase, prostaglandin d2 synthase, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
beta-Trace
Beta-trace protein
Glutathione-dependent PGD synthetase
-
-
-
-
glutathione-dependent prostaglandin D2 synthase
Glutathione-independent PGD synthetase
-
-
-
-
H-PGDS
haematopoietic prostaglandin D synthase
Hematopoietic prostaglandin D synthase
hematopoietic prostaglandin D2 synthase
HPGDS
Isomerase, prostaglanin R2 D-
-
-
-
-
L-PGDS
L-prostaglandin D synthase
L-type prostaglandin synthase
lipocalin prostaglandin D synthase
lipocalin-type PGD synthase
lipocalin-type prostaglandin d synthase
lipocalin-type prostaglandin D2 synthase
PGD synthase
PGD2 synthase
-
-
-
-
PGDS
PGDS2
-
-
-
-
PGH-PGD isomerase
-
-
-
-
Prostaglandin D synthase
Prostaglandin D2 synthase
Prostaglandin-D synthase
Prostaglandin-H2 D-isomerase
Prostaglandin-R-prostaglandin D isomerase
-
-
-
-
PTGDS
beta-Trace
-
-
-
-
Beta-trace protein
-
-
-
-
H-PGDS
-
-
-
-
Hematopoietic prostaglandin D synthase
-
-
-
-
L-PGDS
-
lipocalin-type prostaglandin d synthase
-
PGD synthase
-
-
-
-
PGDS
-
-
-
-
Prostaglandin D synthase
-
-
-
-
Prostaglandin D2 synthase
-
-
-
-
Prostaglandin-D synthase
-
-
-
-
Prostaglandin-H2 D-isomerase
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
(5Z,13E,15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate = (5Z,13E,15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
intramolecular oxidoreduction
-
-
-
-
isomerization
isomerization
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY SOURCE
PATHWAYS
BRENDA
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
(5Z,13E,15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase
Brings about the opening of the epidioxy bridge. Some enzymes require glutathione.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
52227-78-8
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate + 2 GSH
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + GSSG + 2 H+
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate + glutathione
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + glutathione
(5Z,13E,15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E,15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
4-hydroxynon-2-enal + glutathione
?
conjugation of glutathione
-
?
4-nitrobenzyl chloride + glutathione
?
conjugation of glutathione
-
?
7-chloro-4-nitrobenz-2-oxa-1,3-diazole + glutathione
?
conjugation of glutathione
-
?
9,11-epoxymethano-prostaglandin H2
9,11-epoxymethano-prostaglandin D2
substrate analogue U44069
product analogue 12415
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate + glutathione
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + glutathione
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate + glutathione
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + glutathione
-
-
-
?
(5Z,13E,15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E,15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
-
?
(5Z,13E,15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E,15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
-
?
(5Z,13E,15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E,15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
i.e. prostaglandin H2, PGH2
i.e. prostaglandin D2, PGD2
-
?
1-bromo-2,4-dinitrobenzene + glutathione
?
conjugation of glutathione
-
?
1-chloro-2,4-dinitrobenzene + glutathione
?
conjugation of glutathione
-
?
1-fluoro-2,4-dinitrobenzene + glutathione
?
conjugation of glutathione
-
?
1-iodo-2,4-dinitrobenzene + glutathione
?
conjugation of glutathione
-
?
allyl isothiocyanate + glutathione
?
conjugation of glutathione
-
?
benzyl isothiocyanate + glutathione
?
conjugation of glutathione
-
?
cumene hydroperoxide + 2 GSH
cumene hydroxide + GSSG + H2O
-
-
?
Prostaglandin H2
Prostaglandin D2
-
-
-
-
?
Prostaglandin H2
Prostaglandin D2
-
-
-
-
?
additional information
?
-
-
the enzyme may play an important role in both the development and the maturation of sperm
-
-
?
additional information
?
-
prostaglandin D synthase isoforms from cerebrospinal fluid vary with brain pathology
-
-
?
additional information
?
-
lipocalin-type prostaglandin D synthase is a dual-functional protein, acting as a prostaglandin D2-producing enzyme and a lipid transporter, the enzyme can bind a wide variety of lipophilic molecules
-
-
?
additional information
?
-
-
enzyme may play a role in scavenging harmful lipophilic substrates in lysosomal storage disorders
-
-
?
additional information
?
-
-
the lipocalin-type prostaglandin D synthase, prostaglandin D2, and prostaglandin D receptor system plays a pivotal role in the regulation of physiological sleep
-
-
?
additional information
?
-
-
the enzyme is bi-functional capable of synthesising D series prostaglandins and acting as a carrier of small lipophilic molecules
-
-
?
additional information
?
-
-
the enzyme is bi-functional capable of synthesising D series prostaglandins and acting as a carrier of small lipophilic molecules
-
-
?
additional information
?
-
the enzyme is inactive toward 1,2-epoxy-3-(4-nitrophenoxy)-propane, 4-nitrophenethyl bromide, 4-nitrobenzyl chloride, 4-hydroxynonenal, ethacrynic acid, and 4-nitrophenyl acetate
-
-
?
additional information
?
-
-
the enzyme is inactive toward 1,2-epoxy-3-(4-nitrophenoxy)-propane, 4-nitrophenethyl bromide, 4-nitrobenzyl chloride, 4-hydroxynonenal, ethacrynic acid, and 4-nitrophenyl acetate
-
-
?
additional information
?
-
-
the enzyme binds all-trans-retinoic acid or 9-cis-retinoic acid and all-trans-retinal or 13-cis-retinal,but not all-trans-retinol
-
-
?
additional information
?
-
-
the enzyme belongs to the lipocalin family, a group of secretory proteins involved in the transport of small lipophilic ligands
-
-
?
additional information
?
-
-
the enzyme belongs to the lipocalin family, a group of secretory proteins involved in the transport of small lipophilic ligands
-
-
?
additional information
?
-
-
the hematopoietic prostaglandin D synthase is the key enzyme for production of the D and J series of prostanoids in the immune system and mast cells
-
-
?
additional information
?
-
-
the lipocalin-type prostaglandin D synthetase is responsible for the biosynthesis of prostaglandin D2 in the central nervous system and the genital organs and is secreted into the cerebrospinal fluid and the seminal plasma as beta-trace that has retinoid binding activity. It is likely that the enzyme is a bifunctional protein that acts as both retinoid transporter and prostaglandin D2-producing enzyme
-
-
?
additional information
?
-
-
glutathione-dependent enzyme is predicted to function somehow in immune and allergic responses
-
-
?
additional information
?
-
-
may be involved in both the maintenance and maturation of the CNS
-
-
?
additional information
?
-
-
the enzyme activity in rat brain exhibits a circadian fluctuation in parallel with the sleep/wake cycle
-
-
?
additional information
?
-
-
increased secretion of prostaglandin D synthase by interleukin-1beta is completely inhibited by prostaglandin E2
-
-
?
additional information
?
-
-
it is proposed that in wild-type vascular smooth muscle cells the enzyme retards cell cycle progression and migration, precluding hyperplasia of the tunica media, and that diabetic cells appear resistant to inhibitory effects of L-PGDS, which may help explain the increased atherosclerosis observed in diabetes
-
-
?
additional information
?
-
-
lipocalin-type prostaglandin synthase-D can stimulate glucose transport approximately 2fold as well as enhance insulin-stimulated glucose transport due to stimulation of insulin-responsive glucose transporter GLUT4 translocation to the plasma membrane. In response to lipocalin-type prostaglandin synthase-D, there is an increase in GLUT1 expression and an increase in hexokinase III expression
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate + 2 GSH
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + GSSG + 2 H+
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate + glutathione
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + glutathione
(5Z,13E,15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E,15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate + glutathione
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + glutathione
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate + glutathione
(5Z,13E)-(15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + glutathione
-
-
-
?
(5Z,13E,15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E,15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
-
?
(5Z,13E,15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E,15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
-
-
-
?
cumene hydroperoxide + 2 GSH
cumene hydroxide + GSSG + H2O
-
-
?
Prostaglandin H2
Prostaglandin D2
-
-
-
-
?
additional information
?
-
-
the enzyme may play an important role in both the development and the maturation of sperm
-
-
?
additional information
?
-
prostaglandin D synthase isoforms from cerebrospinal fluid vary with brain pathology
-
-
?
additional information
?
-
lipocalin-type prostaglandin D synthase is a dual-functional protein, acting as a prostaglandin D2-producing enzyme and a lipid transporter, the enzyme can bind a wide variety of lipophilic molecules
-
-
?
additional information
?
-
-
enzyme may play a role in scavenging harmful lipophilic substrates in lysosomal storage disorders
-
-
?
additional information
?
-
-
the lipocalin-type prostaglandin D synthase, prostaglandin D2, and prostaglandin D receptor system plays a pivotal role in the regulation of physiological sleep
-
-
?
additional information
?
-
-
the enzyme is bi-functional capable of synthesising D series prostaglandins and acting as a carrier of small lipophilic molecules
-
-
?
additional information
?
-
-
the enzyme is bi-functional capable of synthesising D series prostaglandins and acting as a carrier of small lipophilic molecules
-
-
?
additional information
?
-
-
the enzyme belongs to the lipocalin family, a group of secretory proteins involved in the transport of small lipophilic ligands
-
-
?
additional information
?
-
-
the enzyme belongs to the lipocalin family, a group of secretory proteins involved in the transport of small lipophilic ligands
-
-
?
additional information
?
-
-
the hematopoietic prostaglandin D synthase is the key enzyme for production of the D and J series of prostanoids in the immune system and mast cells
-
-
?
additional information
?
-
-
the lipocalin-type prostaglandin D synthetase is responsible for the biosynthesis of prostaglandin D2 in the central nervous system and the genital organs and is secreted into the cerebrospinal fluid and the seminal plasma as beta-trace that has retinoid binding activity. It is likely that the enzyme is a bifunctional protein that acts as both retinoid transporter and prostaglandin D2-producing enzyme
-
-
?
additional information
?
-
-
glutathione-dependent enzyme is predicted to function somehow in immune and allergic responses
-
-
?
additional information
?
-
-
may be involved in both the maintenance and maturation of the CNS
-
-
?
additional information
?
-
-
the enzyme activity in rat brain exhibits a circadian fluctuation in parallel with the sleep/wake cycle
-
-
?
additional information
?
-
-
increased secretion of prostaglandin D synthase by interleukin-1beta is completely inhibited by prostaglandin E2
-
-
?
additional information
?
-
-
it is proposed that in wild-type vascular smooth muscle cells the enzyme retards cell cycle progression and migration, precluding hyperplasia of the tunica media, and that diabetic cells appear resistant to inhibitory effects of L-PGDS, which may help explain the increased atherosclerosis observed in diabetes
-
-
?
additional information
?
-
-
lipocalin-type prostaglandin synthase-D can stimulate glucose transport approximately 2fold as well as enhance insulin-stimulated glucose transport due to stimulation of insulin-responsive glucose transporter GLUT4 translocation to the plasma membrane. In response to lipocalin-type prostaglandin synthase-D, there is an increase in GLUT1 expression and an increase in hexokinase III expression
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
COFACTOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
glutathione
-
KM for glutathione is decreased from 0.0006 mM in presence of EDTA to 0.00014 mM in presence of Mg2+
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Ca2+
half maximal effective concentration at 0.4 mM, 1.5fold increase in activity
Mg2+
Mg2+
half maximal effective concentration at 0.05 mM, 1.5fold increase in activity, Mg2+ increases the affinity for glutathione
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
2'-methoxy-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl][2,4'-bipyridine]-5-carboxamide
-
2'-oxo-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]-1',2'-dihydro[2,4'-bipyridine]-5-carboxamide
-
2-(2'-benzothiazolyl)-5-styryl-3-(4'-phthalhydrazyl) tetrazolium chloride
-
IC50: 0.0362 mM in presence of EDTA, 0.0981 in presence of Mg2+
3-(3-cyclopropyl-1H-pyrazol-4-yl)-N-ethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide
-
-
6'-oxo-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]-1',6'-dihydro[2,2'-bipyridine]-5-carboxamide
-
6'-oxo-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]-1',6'-dihydro[2,3'-bipyridine]-5-carboxamide
-
6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]pyridine-3-carboxamide
-
-
6-(3-methoxyphenyl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
-
6-(3-oxopiperazin-1-yl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
-
6-(dimethylamino)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
-
6-(morpholin-4-yl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
-
6-(piperazin-1-yl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
-
6-(piperidin-1-yl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
-
6-(pyrrolidin-1-yl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
-
6-phenoxy-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
-
AT-56
-
inhibition of prostaglandin-D synthase, resulting in suppression of prostaglandin D2 production under serum-starved conditions
erythrosine sodium
i.e. disodium 2-(2,4,5,7-tetraiodo-6-oxido-3-oxo-3H-xanthen-9-yl)benzoate
iopanic acid
linear competitive inhibitor, i.e. 2-[(3-amino-2,4,6-triiodophenyl)methyl]butanoic acid
N-(1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)-5-(3-hydroxyphenyl)thiophene-2-carboxamide
N-(5-fluoro-3-methyl-1H-indol-1-yl)-2-(pyridin-2-yl)pyrimidine-5-carboxamide
-
-
N-([4-[5-(2-hydroxypropan-2-yl)-1,2,4-oxadiazol-3-yl]phenyl]methyl)-2-phenylpyrimidine-5-carboxamide
-
N-benzhydryl-5-(3-hydroxyphenyl)thiophene-2-carboxamide
-
low micromolar potency in the inhibition of the purified enzyme
N-cyclopentyl-3-(3-cyclopropyl-1H-pyrazol-4-yl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide
-
66% inhibition at 10 nM
N-methoxy-N-methyl-4-(5-benzoylbenzimidazole-2-yl)-3,5-dimethylpyrrole-2-carboxamide
-
TAS-204, specific H-PGDS inhibitor
N-[4-methyl-3-({3-[(4-methylpiperazin-1-yl)methyl]benzoyl}amino)phenyl]-3-phenyl-1,2-thiazole-5-carboxamide
N-[4-methyl-3-[([3-[(4-methylpiperazin-1-yl)methyl]phenyl]carbonyl)amino]phenyl]-3-phenylisothiazole-5-carboxamide
-
N-[5-(1H-indol-4-yl)pyridin-3-yl]-2-(1-methyl-1H-imidazol-5-yl)acetamide
-
N-[5-(1H-indol-4-yl)pyridin-3-yl]-5-oxopyrrolidine-2-carboxamide (incorrect configuration definition!)
-
Na2SeO3
-
systemic administration of the inhibitor has sleep-reducing potency
Se2+
-
organic selenocompounds have no effect, hexavalent selenium compound is ineffective. The inhibition requires the preincubation of the metal with sulfhydryl compounds such as dithiothreitol, reversal of inhibition by excess amount of dithiothreitol. The rat spleen enzyme is much less inhibited than the rat brain enzyme
tranilast
i.e. 2-{[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino}benzoic acid
2-phenyl-5-(1H-pyrazol-3-yl)-1,3-thiazole
inhibitor generated by fragment-based drug design, crystallographic data
4-dibenzo [a,d]cyclohepten-5-ylidene-1-[4-(2H-tetrazol-5-yl)-butyl]-piperidine
-
i.e. AT-56, inhibits the activity of lipocalin-type prostaglandin-D synthase in a concentration-dependent manner, but does not affect the activities of hematopoietic prostaglandin-D synthase, cyclooxygenase-1 and -2, and microsomal PGE synthase-1. AT-56 inhibits the lipocalin-type prostaglandin-D synthase activity in a competitive manner against the substrate prostaglandin H2 but does not inhibit the binding of 13-cis-retinoic acid. AT-56 occupies the catalytic pocket, but not the retinoid-binding pocket, of lipocalin-type prostaglandin-D synthase
4-dibenzo [a,d]cyclohepten-5-ylidene-1-[4-(2H-tetrazol-5-yl)-butyl]-piperidine
i.e. AT-56. Orally administered AT-56 below 30 mg/kg body weight decreases the prostaglandin D2 production to 40% in the brain of H-PGDS-deficient mice after a stab-wound injury in a dose-dependent manner without affecting the production of prostaglandin E2 and prostaglandin F2alpha, and also suppresses the accumulation of eosinophils and monocytes in the bronco-alveolar lavage fluid from the antigen-induced lung inflammation model of human L-PGDS-transgenic mice
4-[[4-(4-fluoro-3-methylphenyl)-1,3-thiazol-2-yl]amino]-2-hydroxybenzoic acid
-
4-[[4-(4-fluoro-3-methylphenyl)-1,3-thiazol-2-yl]amino]-2-hydroxybenzoic acid
-
-
4-[[4-(4-fluoro-3-methylphenyl)-1,3-thiazol-2-yl]amino]-2-hydroxybenzoic acid
-
-
6-(3-fluorophenyl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
-
6-(3-fluorophenyl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
-
-
Ethacrynic acid
i.e. [2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid
HQL-79
-
i.e. 4-benzhydryloxy-1-[3-(1H-tetrazol-5-yl)-propyl]-piperidine, H-PGDS-specific inhibitor
N-(1-amino-1-oxo-3-phenylpropan-2-yl)-5-(3-hydroxyphenyl)-thiophene-2-carboxamide
-
-
N-(1-amino-1-oxo-3-phenylpropan-2-yl)-5-(3-hydroxyphenyl)-thiophene-2-carboxamide
-
-
N-(1-amino-1-oxo-3-phenylpropan-2-yl)-6-(thiophen-2-yl)nicotinamide
-
selective H-PGDS inhibitor with low micromolar potency in the inhibition of the purified enzyme
N-(1-amino-1-oxo-3-phenylpropan-2-yl)-6-(thiophen-2-yl)nicotinamide
-
selective H-PGDS inhibitor with low micromolar potency in the inhibition of the purified enzyme
N-(1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-3'-hydroxybiphenyl-4-carboxamide
-
-
N-(1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-3'-hydroxybiphenyl-4-carboxamide
-
-
N-(1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-5-(3-hydroxyphenyl)thiophene-2-carboxamide
-
-
N-(1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-5-(3-hydroxyphenyl)thiophene-2-carboxamide
-
-
N-(1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)-5-(3-hydroxyphenyl)thiophene-2-carboxamide
-
-
N-(1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)-5-(3-hydroxyphenyl)thiophene-2-carboxamide
-
-
N-(1-amino-3-cyclohexyl-1-oxopropan-2-yl)-5-(1H-indol-4-yl)thiophene-2-carboxamide
-
-
N-(1-amino-3-cyclohexyl-1-oxopropan-2-yl)-5-(1H-indol-4-yl)thiophene-2-carboxamide
-
-
N-(1-amino-4-methyl-1-oxopentan-2-yl)-5-(3-hydroxyphenyl)-thiophene-2-carboxamide
-
-
N-(1-amino-4-methyl-1-oxopentan-2-yl)-5-(3-hydroxyphenyl)-thiophene-2-carboxamide
-
-
N-[4-methyl-3-({3-[(4-methylpiperazin-1-yl)methyl]benzoyl}amino)phenyl]-3-phenyl-1,2-thiazole-5-carboxamide
-
-
N-[4-methyl-3-({3-[(4-methylpiperazin-1-yl)methyl]benzoyl}amino)phenyl]-3-phenyl-1,2-thiazole-5-carboxamide
-
-
Se4+
-
organic selenocompounds have no effect, hexavalent selenium compound is ineffective. The inhibition requires the preincubation of the metal with sulfhydryl compounds such as dithiothreitol, reversal of inhibition by excess amount of dithiothreitol. The rat spleen enzyme is much less inhibited than the rat brain enzyme
Se4+
-
SeCl4; systemic administration of the inhibitor has sleep-reducing potency
SeCl4
-
selective inhibition of enzyme. Intraperitoneal injection of SeCl4 decreases the prostaglandin D2 content in the brain without affecting the amounts of prostaglandins E2 and F2alpha. It inhibits sleep dose-dependently and immediately after the administration
additional information
the lipid transporter activity of the enzyme is competitively inhibited by pamitate, stearate and arachnoate
-
additional information
-
the lipid transporter activity of the enzyme is competitively inhibited by pamitate, stearate and arachnoate
-
additional information
-
not inhibited by oleamide, palmitoylethanolamide, oleoylethanolamide, prostamide F2alpha, N-arachidonoylethanolamine/anandamide, and 2-arachidonoylglycerol
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
arrestin-3
-
arrestin-3 promotes prostaglandin D2 production by L-PGDS in vitro. Incubation of L-PGDS with arrestin-3 amino acids 56-100 enhances prostaglandin D2 production by 145%
-
glutathione
-
the hematopoietic prostaglandin D synthase is a glutathione S-transferase
glutathione
-
the glutathione-requiring enzyme is a member of the glutathione S-transferase family
glutathione
-
the spleen-type PGD synthase is a kind of glutathione S-transferase and therefore requires glutathione for activity
glutathione
-
glutathione-independent enzyme is detected in: brain, spinal cord, epididymis
glutathione
-
glutathione-requiring enzyme is detected in: spleen, thymus, bone marrow, digestive tract, mast cells, histiocytes, dendritic cells, Kupffer cells, Langerhans cells
glutathione
-
required for activity of spleen enzyme, not required for brain enzyme
guanidinium hydrochloride
-
activation between 100-1000 mM, 3fold activation at 500 mM guanidinium hydrochloride, inhibition above 500 mM, less than 5% activity at 3 M
guanidinium hydrochloride
2.5fold activation at 500 mM, inhibition above, less than 5% activity at 2 M guanidinium hydrochloride
guanidinium hydrochloride
activation up to 750 mM, 1.5fold activition at 500 mM, inhibition above 1 M, complete deactivation at 4 M
Urea
-
activation between 250-2000 mM, 1.7fold activation at 1 M urea, inhibition above 500 mM, less than 5% activity at 4 M
Urea
1.6fold activation at 1M, inhibition above, less than 5% activity at 4 M urea
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0023
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
in the presence of 1 M urea
0.0028
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
-
0.0083
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
in the presence of 500 mM guanidinium hydrochloride
0.014
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
-
pH 8.0
0.014
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
pH 8.0
0.2
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
-
0.5
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
-
3
1-chloro-2,4-dinitrobenzene
conjugation of glutathione to 1-chloro-2,4-dinitrobenzene
0.5
glutathione
conjugation of glutathione to 1-chloro-2,4-dinitrobenzene
0.0102
prostaglandin H2
mutant enzyme S81A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
0.0123
prostaglandin H2
mutant enzyme K59A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
0.0127
prostaglandin H2
mutant enzyme Y149A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
0.0138
prostaglandin H2
wild type enzyme, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
0.0154
prostaglandin H2
mutant enzyme T147A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
0.0161
prostaglandin H2
mutant enzyme W54A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
0.0202
prostaglandin H2
mutant enzyme M94A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
0.0204
prostaglandin H2
mutant enzyme S45A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
0.0245
prostaglandin H2
mutant enzyme F83A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
0.0252
prostaglandin H2
mutant enzyme L131A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
0.0325
prostaglandin H2
mutant enzyme M64A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
0.0328
prostaglandin H2
mutant enzyme L79A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
5
1-chloro-2,4-dinitrobenzene
conjugation of glutathione to 1-chloro-2,4-dinitrobenzene
0.37
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
-
0.5
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
in the presence of 1 M urea
0.95
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
in the presence of 500 mM guanidinium hydrochloride
21.7
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
-
2
glutathione
conjugation of glutathione to 1-chloro-2,4-dinitrobenzene
0.06
prostaglandin H2
mutant enzyme L79A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
0.63
prostaglandin H2
mutant enzyme M64A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
0.81
prostaglandin H2
mutant enzyme L131A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
0.87
prostaglandin H2
mutant enzyme F83A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
2.23
prostaglandin H2
mutant enzyme S45A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
2.24
prostaglandin H2
mutant enzyme M94A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
2.4
prostaglandin H2
mutant enzyme W54A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
2.64
prostaglandin H2
wild type enzyme, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
2.91
prostaglandin H2
mutant enzyme S81A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
3.67
prostaglandin H2
mutant enzyme T147A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
5.73
prostaglandin H2
mutant enzyme Y149A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
5.84
prostaglandin H2
mutant enzyme K59A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
110
prostaglandin H2
mutant enzyme L79A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
1170
prostaglandin H2
mutant enzyme M64A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
1890
prostaglandin H2
mutant enzyme L131A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
2120
prostaglandin H2
mutant enzyme F83A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
6570
prostaglandin H2
mutant enzyme S45A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
6660
prostaglandin H2
mutant enzyme M94A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
8940
prostaglandin H2
mutant enzyme W54A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
9420
prostaglandin H2
mutant enzyme S81A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
11490
prostaglandin H2
wild type enzyme, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
14290
prostaglandin H2
mutant enzyme T147A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
24840
prostaglandin H2
mutant enzyme K59A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
27050
prostaglandin H2
mutant enzyme Y149A, in 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM dithiothreitol, at 25°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.075
4-dibenzo [a,d]cyclohepten-5-ylidene-1-[4-(2H-tetrazol-5-yl)-butyl]-piperidine
-
pH 8.0
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
7
2'-oxo-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]-1',2'-dihydro[2,4'-bipyridine]-5-carboxamide
Homo sapiens
at 37°C, pH not specified in the publication
0.0362
2-(2'-benzothiazolyl)-5-styryl-3-(4'-phthalhydrazyl) tetrazolium chloride
Homo sapiens
-
IC50: 0.0362 mM in presence of EDTA, 0.0981 in presence of Mg2+
0.0007
2-phenyl-5-(1H-pyrazol-3-yl)thiazole
Homo sapiens
-
in 0.1 M Tris-HCl, pH 8.0, at 25°C
0.00004
3-(3-cyclopropyl-1H-pyrazol-4-yl)-N-ethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.017
3-(3-cyclopropyl-1H-pyrazol-4-yl)pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.0003
3-acetamido-N-[5-(1H-indol-4-yl)pyridin-3-yl]propanamide
Homo sapiens
at 37°C, pH not specified in the publication
0.00018
4-(dimethylamino)-N-[5-(1H-indol-4-yl)pyridin-3-yl]butanamide
Homo sapiens
at 37°C, pH not specified in the publication
0.003
4-dibenzo [a,d]cyclohepten-5-ylidene-1-[4-(2H-tetrazol-5-yl)-butyl]-piperidine
Homo sapiens
-
inhibition of enzyme in lipocalin-type prostaglandin-D synthase-expressing TE-671 cells after stimulation with Ca2+-ionophore A23187
0.000138 - 0.0014
4-[[4-(4-fluoro-3-methylphenyl)-1,3-thiazol-2-yl]amino]-2-hydroxybenzoic acid
0.0019
5-(3-aminophenyl)-N-benzhydrylthiophene-2-carboxamide
Homo sapiens
-
in 0.1 M Tris-HCl, pH 8.0, at 25°C
0.023
5-amino-4-[[(3'-hydroxybiphenyl-4-yl)carbonyl]amino]-5-oxopentanoic acid
Homo sapiens
-
in 0.1 M Tris-HCl, pH 8.0, at 25°C
0.000071
6'-oxo-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]-1',6'-dihydro[2,2'-bipyridine]-5-carboxamide
Homo sapiens
at 37°C, pH not specified in the publication
0.00006
6-(3-methoxyphenyl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
Homo sapiens
at 37°C, pH not specified in the publication
0.00059
6-(3-oxopiperazin-1-yl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
Homo sapiens
at 37°C, pH not specified in the publication
0.00032
6-(morpholin-4-yl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
Homo sapiens
at 37°C, pH not specified in the publication
0.000048
6-(piperidin-1-yl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
Homo sapiens
at 37°C, pH not specified in the publication
0.00023
6-(pyrrolidin-1-yl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
Homo sapiens
at 37°C, pH not specified in the publication
0.000031
6-phenoxy-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
Homo sapiens
at 37°C, pH not specified in the publication
0.0046
N-(1-amino-1-oxo-3-phenylpropan-2-yl)-3'-hydroxybiphenyl-4-carboxamide
Homo sapiens
-
in 0.1 M Tris-HCl, pH 8.0, at 25°C
0.0248
N-(1-amino-1-oxo-3-phenylpropan-2-yl)-3,3'-dihydroxybiphenyl-4-carboxamide
Homo sapiens
-
in 0.1 M Tris-HCl, pH 8.0, at 25°C
0.0037
N-(1-amino-1-oxo-3-phenylpropan-2-yl)-5-(3-hydroxyphenyl)-thiophene-2-carboxamide
Homo sapiens
-
in 0.1 M Tris-HCl, pH 8.0, at 25°C
0.0012
N-(1-amino-1-oxo-3-phenylpropan-2-yl)-6-(thiophen-2-yl)nicotinamide
Homo sapiens
-
in 0.1 M Tris-HCl, pH 8.0, at 25°C
0.001
N-(1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-3'-hydroxybiphenyl-4-carboxamide
Homo sapiens
-
in 0.1 M Tris-HCl, pH 8.0, at 25°C
0.0021
N-(1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-5-(3-hydroxyphenyl)thiophene-2-carboxamide
Homo sapiens
-
in 0.1 M Tris-HCl, pH 8.0, at 25°C
0.0013
N-(1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)-5-(3-hydroxyphenyl)thiophene-2-carboxamide
Homo sapiens
-
in 0.1 M Tris-HCl, pH 8.0, at 25°C
0.0071
N-(1-amino-4-methyl-1-oxopentan-2-yl)-5-(3-hydroxyphenyl)-thiophene-2-carboxamide
Homo sapiens
-
in 0.1 M Tris-HCl, pH 8.0, at 25°C
0.008
N-(2-amino-2-oxoethyl)-5-(3-hydroxyphenyl)thiophene-2-carboxamide
Homo sapiens
-
in 0.1 M Tris-HCl, pH 8.0, at 25°C
0.0108
N-(diphenylmethyl)-2-(3-hydroxyphenyl)-1,3-thiazole-4-carboxamide
Homo sapiens
-
in 0.1 M Tris-HCl, pH 8.0, at 25°C
0.0007
N-benzhydryl-5-(3-hydroxyphenyl)thiophene-2-carboxamide
Homo sapiens
-
in 0.1 M Tris-HCl, pH 8.0, at 25°C
0.0085
N-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
Homo sapiens
-
pH and temperature not specified in the publication
0.0005
N-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Homo sapiens
-
pH and temperature not specified in the publication
0.000075
N-[4-methyl-3-[([3-[(4-methylpiperazin-1-yl)methyl]phenyl]carbonyl)amino]phenyl]-3-phenylisothiazole-5-carboxamide
Homo sapiens
37°C
0.0012
N-[5-(1H-indol-4-yl)pyridin-3-yl]-2-(1-methyl-1H-imidazol-5-yl)acetamide
Homo sapiens
at 37°C, pH not specified in the publication
0.000043
N-[5-(1H-indol-4-yl)pyridin-3-yl]-2-(1H-tetrazol-1-yl)acetamide
Homo sapiens
at 37°C, pH not specified in the publication
0.00013
N-[5-(1H-indol-4-yl)pyridin-3-yl]-3-(piperidin-1-yl)propanamide
Homo sapiens
at 37°C, pH not specified in the publication
0.000026
N-[5-(1H-indol-4-yl)pyridin-3-yl]-3-(pyridin-3-yl)propanamide
Homo sapiens
at 37°C, pH not specified in the publication
0.000035
N-[5-(1H-indol-4-yl)pyridin-3-yl]-5-oxopyrrolidine-2-carboxamide (incorrect configuration definition!)
Homo sapiens
at 37°C, pH not specified in the publication
0.000032
N-[5-(1H-indol-4-yl)pyridin-3-yl]propanamide
Homo sapiens
at 37°C, pH not specified in the publication
0.000138
4-[[4-(4-fluoro-3-methylphenyl)-1,3-thiazol-2-yl]amino]-2-hydroxybenzoic acid
Homo sapiens
37°C
0.0014
4-[[4-(4-fluoro-3-methylphenyl)-1,3-thiazol-2-yl]amino]-2-hydroxybenzoic acid
Homo sapiens
-
in 0.1 M Tris-HCl, pH 8.0, at 25°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
14.9
14.9
chimeric protein construct carrying the mouse amino-terminal portion from D25 to L84, and zebrafish carboxyl-terminal portion from K79 to A184
14.9
-
chimeric protein construct carrying the mouse amino-terminal portion from D25 to L84, and zebrafish carboxyl-terminal portion from K79 to A184
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
25
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pI VALUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
additional information
-
isolation of several enzyme isoforms with pI values ranging from 4.4 to 6.4
additional information
-
isolation of several enzyme isoforms with pI values ranging from 4.0 to 7.2, with identical molecular masses around 28000 Da
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
homologue of lipocalin-type prostaglandin synthase, no enzymic activity
SwissProt
brenda
homologue of lipocalin-type prostaglandin synthase, weak enzymic activity
SwissProt
brenda
lipocalin-type prostaglandin D synthase. Isoform is identical to beta-trace, a major protein in human cerebrospinal fluid, and acts as both a PGD2-producing enzyme and as an extracellular transporter for lipophilic ligands
-
-
brenda
patients with stable coronary artery disease who underwent diagnostic coronary angiography
-
-
brenda
ApcMin/+ mice bearing a defect in the adenomatous polyposis coli gene which leads to development of many adenomas
-
-
brenda
mouse model of globoid cell leukodystrophy or Krabbes disease, of Tay-Sachs disease, Sandhoff disease, GM1 gangliosidosis and Niemann-Pick type C1 disease
-
-
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
-
lipocalin-type prostaglandin D synthase (beta-trace) is upregulated in the alphaB-crystallin-positive astrocytes in the chronic multiple sclerosis
brenda
-
enzyme is found in luminal and glandular epithelial cells and in stroma during late pregnancy
brenda
-
enzyme is found in luminal and glandular epithelial cells and in stroma during late pregnancy
brenda
-
L-PGDS is constitutively expressed in the epithelium of the glandular base
brenda
-
precursor cells of platelets, CMK cells, Dami cells. The activity is undetectable in platelets and appears during differentiation of megakaryoblasts to megakaryocytes
brenda
-
CMK86, CMK, CMK11-5 and Dami cells. Expression level is highest in CMK86 cells and is less in CMK cells, CMK11-5 cells and Dami cells in that order
brenda
-
human ovarian cancer cells. Prostaglandin synthase and testicular factor SOX9 are expressed at both RNA and protein levels in different types of ovarian tumors, while treatment of these cells with prostaglandin D2 can inhibit their growth and induce apoptosis
brenda
-
determination of the correlation between content of enzyme in seminal plasma and on the surface of sperm
brenda
-
under serum-starved conditions, prostaglandin D2 production is induced through transcriptional activation of cyclooxygenase COX-2 and lipocalin-type PGD synthase via upstream stimulatory factor USF1
brenda
-
of cyclic, pregnant, and pseudopregnant rats. Expression of prostaglandin D synthase or prostacyclin synthase are not influenced by the estrous cycle. Prostaglandion D synthase expression is high during early and maximal at the end of pregnancy. During pseudopregnancy, enzyme is increased in time-dependent manner and maximal at day 5
brenda
synthesized mainly at the rough endoplasmic reticulum membrane of arachnoid cells, chorioid plexus cells and oligodendrocytes, and then is secreted into the cerebrospinal fluid as a second major protein
brenda
-
enzyme mRNA is up-regulated in mouse model of globoid cell leukodystrophy or Krabbes disease, of Tay-Sachs disease, Sandhoff disease, GM1 gangliosidosis and Niemann-Pick type C1 disease,. Oligodendrocytes of all these mouse models show strong immunoreactivity for enzyme, but not astrocytes or microglia
brenda
-
cellular localization of the enzyme changes postnatally. The enzyme is distributed in most neurons of the brain of 1-2 week old rats, whereas it is localized in the oligodendrocytes of adult animals
brenda
-
prostaglandin-H2 D-isomerase is produced in the membrane system surrounding the brain and is secreted into the cerebrospinal fluid to become beta-trace
brenda
qualitative and quantitative fluctuations of prostaglandin D synthase isoforms from cerebrospinal fluid reflect both major and subtle brain pathophysiology
brenda
-
L-PGDS expression in mouse epididymis gradually declines in parallel to the declining concentration of endogenous androgen after castration and increases with the treatment of exogenous testosterone
brenda
-
bone-marrow derived macrophage, lung and alveolar macrophage. Treatment with Escherichia coli lipopolysaccharide or Pseudomonas induce enzyme expression. Induction is regulated positively by AP-1 and negatively by p53
brenda
-
in normal mucosa the enzyme is only detected in few resident mast cells. In the nasal mucosa of subjects suffering from polyposis the enzyme is detected in mast cells and other large infiltrating inflammatory cells
brenda
-
in normal mucosa the enzyme is only detected in few resident mast cells. In the nasal mucosa of subjects suffering from polyposis the enzyme is detected in mast cells and other large infiltrating inflammatory cells
brenda
-
lipocalin-type prostaglandin D synthase (beta-trace) is upregulated in the alphaB-crystallin-positive oligodendrocytes in the chronic multiple sclerosis
brenda
the enzyme is predominantly expressed in retinal pigment epithelium and actively accumulates in interphotoreceptor matrix
brenda
-
the enzyme is synthesized within the epithelial cells of the iris and the ciliary body and is then secreted into the aqueous and vitreous humors, where it accumulates as an active enzyme
brenda
-
both L-PGDS mRNA and protein are highly expressed in the interstitial tissue of adult testis. L-PGDS mRNA is first detected on day 30 after birth and exhibits an abundant signal in adult caput and cauda epididymis
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
-
perinuclear L-type prostaglandin synthase/arrestin-3 co-localization is observed in prostaglandin D2-producing MG-63 cells
brenda
the N-terminal 22-amino acid residues correspond to the putative secretion signal peptide of the enzyme
-
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
evolution
malfunction
physiological function
additional information
malfunction
-
co-localization of arrestin-3 with L-PGDS is drastically reduced in MG-63 cells when L-PGDS activity is inhibited
malfunction
-
dextran sodium sulfate treatment to L-PGDS-deficientmice shows lower ulcerative colitis disease activity than control mice
malfunction
-
the stable transfection with antisense L-PGDS induces markedly the stimulation of fat storage in cultured adipocytes during the maturation phase
malfunction
-
double knockout mice, lacking lipocalin prostaglandin D synthase as well as PPARgamma2, have impaired carbohydrate and lipid metabolism with glucose tolerance compared to any other genotypes, their interscapular brown adipose tissue exhibits greater lipid content than that of wild-type mice, which is independent of PPARgamma2 dysfunction. In subcutaneous white adipose tissue, L-PGDS KO mice exhibit a 4fold increase in UCP1 expression and a reduction in adipogenic marker aP2 expression. Phenotypes, overview
malfunction
-
enzyme deficiency accelerates the growth of melanoma in mice. Enzyme deficiency results in functional changes of tumor endothelial cells such as accelerated vascular hyperpermeability, angiogenesis, and endothelial-to-mesenchymal transition in tumors, which in turn reduce tumor cell apoptosis
malfunction
the incidence of preterm birth is significantly reduced to 40% in enzyme-deficient knockout mice
malfunction
-
double knockout mice, lacking lipocalin prostaglandin D synthase as well as PPARgamma2, have impaired carbohydrate and lipid metabolism with glucose tolerance compared to any other genotypes, their interscapular brown adipose tissue exhibits greater lipid content than that of wild-type mice, which is independent of PPARgamma2 dysfunction. In subcutaneous white adipose tissue, L-PGDS KO mice exhibit a 4fold increase in UCP1 expression and a reduction in adipogenic marker aP2 expression. Phenotypes, overview
-
physiological function
-
L-PGDS may fine-tune the all-trans retinoic acid signaling in melanocytes
physiological function
lipocalin type prostaglandin D synthase is a multi-functional protein acting as a somnogen (PGD2)-producing enzyme, an extracellular transporter of various lipophilic ligands, and an amyloid-beta chaperone in human cerebrospinal fluid
physiological function
lipocalin-type prostaglandin D synthase acts as both a PGD2 synthase and an extracellular transporter for small lipophilic molecules
physiological function
-
H-PGDS plays a critical role in the development of allergic rhinitis, especially in the induction of late phase nasal obstruction
physiological function
lipocalin prostaglandin D synthase regulates synthesis of an important inflammatory and signaling mediator, prostaglandin D2
physiological function
lipocalin-type prostaglandin D synthase is a multi-functional protein, acting as a prostaglandin D2-producing enzyme and a lipid-transporter. It is involved in the biosynthesis of prostaglandin D2, acting as an endogenous somnogen and allergy response. Binding mechanism of small lipophilic molecules by the enzyme functioning as lipid transporter, e.g. of biliverdin, all-trans-retinoic acid, L-thyroxine (T4), progesterone, and genistein, thermodynamic parameters, overview. The enzme shows broad ligand selectivity for small lipophilic molecules, it binds heme metabolites with significantly higher affinity than other small lipophilic ligands
physiological function
-
requirement of the enzyme for maintenance of subcutaneous white adipose tissue function. The enzyme and peroxisome proliferator-activated receptor gamma2 coordinate to regulate carbohydrate and lipid metabolism
physiological function
the enzyme shows a protective effect on H2O2-induced apoptosis in neuroblastoma cell line SH-SY5Y, the enzyme level is highly associated with H2O2-induced apoptosis. It protects against neuronal cell death by scavenging reactive oxygen species without losing its ligand-binding function. H2O2 reacts with the thiol of Cys65 of the enzyme
physiological function
higher enzyme concentrations significantly reduce the secretion of glucagon in alpha cells, which may contribute to the pathogenesis of diabetes
physiological function
-
the enzyme has dual functional roles as a prostaglandin D2-synthesizing enzyme and as an extracellular transporter for diverse lipophilic compounds in the cerebrospinal fluid
physiological function
the enzyme plays a role in lipopolysaccharide-induced preterm birth
physiological function
-
requirement of the enzyme for maintenance of subcutaneous white adipose tissue function. The enzyme and peroxisome proliferator-activated receptor gamma2 coordinate to regulate carbohydrate and lipid metabolism
-
additional information
analysis of enzyme structure in complex with substrate analogue U44069, 9,11-epoxymethano-PGH2, and in ligand-free form. The catalytic Cys 65 thiol group occurs in two different conformations, each making a distinct hydrogen bond network to neighboring residues, mechanism of the cysteine nucleophile activation, and modelling of dynamics of protein-substrate and protein-product interactions, overview
additional information
-
analysis of enzyme structure in complex with substrate analogue U44069, 9,11-epoxymethano-PGH2, and in ligand-free form. The catalytic Cys 65 thiol group occurs in two different conformations, each making a distinct hydrogen bond network to neighboring residues, mechanism of the cysteine nucleophile activation, and modelling of dynamics of protein-substrate and protein-product interactions, overview
additional information
binding of various lipophilic ligands in the hydrophobic cavity of lipocalin-type prostaglandin D synthase, i.e. hemin, biliverdin, and bilirubin, retinoids (all-trans and 9-cis retinoic acids), thyroids, steroids (progesterone, testosterone, and corticosterone), flavonoids (genistein, naringenin, and daidzein), the substrate PGH2 analogue U46619, and the fluorescence probe TNS, buffer-independent thermodynamic parameters, overview. The broad binding capability of the enzyme for ligands is realized by hydrophilic interactions delicately tuned by enthalpy-entropy compensation using combined effects of hydrophilic and hydrophobic interactions
additional information
-
binding of various lipophilic ligands in the hydrophobic cavity of lipocalin-type prostaglandin D synthase, i.e. hemin, biliverdin, and bilirubin, retinoids (all-trans and 9-cis retinoic acids), thyroids, steroids (progesterone, testosterone, and corticosterone), flavonoids (genistein, naringenin, and daidzein), the substrate PGH2 analogue U46619, and the fluorescence probe TNS, buffer-independent thermodynamic parameters, overview. The broad binding capability of the enzyme for ligands is realized by hydrophilic interactions delicately tuned by enthalpy-entropy compensation using combined effects of hydrophilic and hydrophobic interactions
additional information
structure homology modelling using the solution structure of the C65A mouse L-PGDS, PDB code 2RQ0, as template, overview
Show AA Sequence and Transmembrane Helices (276 entries)
Please use the AA Sequence and Transmembrane Helices Search for a specific query.
Please use the AA Sequence and Transmembrane Helices Search for a specific query.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PDB
SCOP
CATH
UNIPROT
ORGANISM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
23000
25000
26000
28000
-
x * 28000, SDS-PAGE, molecular mass is the same for several isoforms showing pI values from 4.2 to 7.0
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
homodimer
monomer
additional information
?
-
x * 28000, SDS-PAGE, molecular mass is the same for several isoforms showing pI values from 4.2 to 7.0
additional information
analysis of enzyme structure in complex with substrate analogue U44069, 9,11-epoxymethano-PGH2, and in ligand-free form, NMR analysis, overview. The enzyme overall structure shows the classical lipocalin fold comprising an eight-stranded beta-barrel with two alpha-helices. The ligand-bound and the ligand-free structures differ only in the Omega loop conformationss
additional information
-
analysis of enzyme structure in complex with substrate analogue U44069, 9,11-epoxymethano-PGH2, and in ligand-free form, NMR analysis, overview. The enzyme overall structure shows the classical lipocalin fold comprising an eight-stranded beta-barrel with two alpha-helices. The ligand-bound and the ligand-free structures differ only in the Omega loop conformationss
additional information
structure homology modelling using the solution structure of the C65A mouse L-PGDS, PDB code 2RQ0, as template, overview
additional information
three-dimensional structure of the enzyme and its hydrophobic cavaity, overview. The secondary structure elements of the enzyme comprise nine beta-strands and four alpha-helices
additional information
-
three-dimensional structure of the enzyme and its hydrophobic cavaity, overview. The secondary structure elements of the enzyme comprise nine beta-strands and four alpha-helices
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
glycoprotein
glycoprotein
-
the two N-glycosylation sites are almost quantitatively occupied by carbohydrate. Asn29 and Asn56 bear exclusively complex-type oligosaccharide structures, partially sialylated with alpha2-3- and/or alpha2-6-linked N-acetylneuraminic acid, that are almost quantitatively alpha1-6 fucosylated at the proximal N-acetylglucosamine. About 70% of the molecules contain a bisecting N-acetylglucosamine. Agalacto-structures as well as those with a peripheral fucose are also present
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
crystals of H-PGDS are first grown by hanging-drop vapor diffusion method with PEG6000 as the precipitant at 20°C in the presence of 5 mM Mg2+ and the native crystals are then soaked in the precipitant solution with a saturating concentration of 2-(2'-benzothiazolyl)-5-styryl-3-(4'-phthalhydrazyl) tetrazolium chloride for 2 weeks. Structure of the enzyme complexed with 2-(2'-benzothiazolyl)-5-styryl-3-(4'-phthalhydrazyl) tetrazolium chloride at 1.9 A resolution in the presence of Mg2+. The styryl group of the inhibitor penetrates to the bottom of the active site cleft, and the tetrazole ring is stabilized by the stacking interaction with TRp104, inducing large movement around the alpha5-helix, which causes the space group of the complex crystal to change from P2(1) to P1 upon binding of 2-(2'-benzothiazolyl)-5-styryl-3-(4'-phthalhydrazyl) tetrazolium chloride
-
H-PGDS is crystallized in a microgravity environment at 20°C, using 30% (w/v) PEG 6000, 10 mM dithiothreitol, 10 mM glutathione, 1% (v/v) dioxane and 1 mM magnesium chloride in 50 mM Tris-HCl pH 8.4
-
hanging drop vapor diffusion method, using 0.1 M MES/NaOH at pH 6.5, 0.005 M MgCl2 and 24% (w/v) PEG 3350
-
macro-seeding using a solution containing 14% polyethylene glycol 6000, 50 mM Tris-HCl, pH 8.4, 5 mM reduced glutathione, 5 mM dithiothreitol, 2.5 mM CaCl2 or MgCl2 and 1% dioxane, structure resolution at 1.8 A
mutant C65A in complex with oleic acid and palmitoleic acid, hanging drop vapor diffusion method, using 0.1 M citric acid (pH 4.0) and 1.7 M ammonium sulfate
mutant enzymes C65A/K59A, C65A, C65A/W54F, C65A/W112F and C65A/W54F/W112F hanging drop vapor diffusion method, using 0.2 M ammonium sulfate, 30% (w/v) PEG 4000
purified His-tagged recombinant enzyme, in complex with 9,11-epoxymethano prostaglandin H2, hanging drop vapor diffusion method, condition A: 0.1 M potassium thiocyanate and 30% PEG-MME 2000 in 1:1 protein-reservoir ratio, 5 days, 4°C, condition B: 1.4 M tri-sodium citrate, pH 6.5, using a similar method except in 2:1 protein-reservoir ratio. Micro-crystals from condition A are used to seed crystallization of ligand-free L-PGDS in the same condition but in the absence of SA U44069. Cryoprotection of condition A crystals using reservoir with 25% glycerol added, while crystals from condition B are cryo-protected with 1.6 M tri-sodium citrate solution. X-ray diffraction structure analysis at 1.88-2.09 A resolution
the structure of H-PGDS in complex with GSH and nocodazole is solved to a resolution of 1.9 A
mutant DELTA1-24_C65A L-PGDS is crystallized in two different crystal forms representing the conformational change between the open and closed states of the cavity of the beta-barrel, the structures are determined to resolutions of 2.1 and 2.0 A
NMR solution structure, enzyme consists of an eight-stranded, antiparallel beta-barrel and a long alpha-helix associated with the outer surface of the barrel. The interior of the barrel forms a hydrophobic cavity containing two pockets. Prostaglandin H2 almost fully occupies hydrophilic pocket 1, in which C65 is located, and all-trans retinoic acid occupies hydrophilic pocket 2
in complex with glutathione, sitting drop vapor diffusion method, using 0.1 M Tris-HCl, pH 8.0, 28% (w/v) PEG4000
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
G59C
C59 is an essential residue for enzyme activity in mammals. Mutant G59C does not show enzymic activity
C65A/C167A
D96N
very high basal activity, no activation in the presence of Ca2+ or Mg2+
W43F/C65A/C167A
site-directed mutagenesis, the W43F mutant cannot be purified owing to the inclusion body formation of protein
W54F/C65A/W112F/C167A
site-directed mutagenesis, the mutant still provides the disulfide bond between Cys89 and Cys186
C65A
-
mutant binds all-trans-retinoic acid, bilirubin and biliverdin with high affinity. Radius of gyration is 19.4 A for the free enzyme, and it become compact after binding of these ligands
DELTA1-24_C65A L-PGDS
mutant, preserves a disulfide bond between Cys89 and Cys186
A106S
-
creation of a new protein kinase C phosphorylation site, significant inhibition of the ability of enzyme to induce apoptosis and significant decrease in catalytic activity
C156L
loss of prostaglandin D synthase activity, retention of glutathione S-transferase activity
C156Y
loss of prostaglandin D synthase activity, retention of glutathione S-transferase activity
C186A
C65A
C65A/C89A/C186A
-
mutant is properly folded with well-defined tertiary structures
C89A/C186A
D51A
-
creation of new glycosylation site 1, significant inhibition of the ability of enzyme to induce apoptosis and significant decrease in catalytic activity
D78A
-
creation of new glycosylation site 2, no significant changes in enzyme activity or ability to induce apoptosis
K112E
retention of prostaglandin D synthase and glutathione S-transferase activity
K198E
retention of prostaglandin D synthase and glutathione S-transferase activity
L199F
retention of prostaglandin D synthase and glutathione S-transferase activity
R14E
complete loss of prostaglandin D synthase activity and glutathione S-transferase activity
R14K
complete loss of prostaglandin D synthase activity and glutathione S-transferase activity
W104I
complete loss of prostaglandin D synthase activity and glutathione S-transferase activity
Y152F
retention of prostaglandin D synthase and glutathione S-transferase activity
Y8F
complete loss of prostaglandin D synthase activity and glutathione S-transferase activity
additional information
C65A/C167A
site-directed mutagenesis, the mutant still provides the disulfide bond between Cys89 and Cys186
C65A/C167A
site-directed mutagenesis, the mutation limits incorrect intra- and intermolecular disulfide bonds and protein aggregation during recombinant enzyme expression and purification
C186A
-
no significant change in conformation. Decrease in stability and in dissociation constants for 8-anilino-1-naphthalenesulfonic acid and retinoic acid. Urea-induced unfolding at 2.875 mol/l compared with 5.75 mol/l for wild-type
C65A
-
mutation of active site, significant inhibition of the ability of enzyme to induce apoptosis and significant decrease in catalytic activity
C65A
-
no significant change in conformation. Urea-induced unfolding at 5.125 mol/l compared with 5.75 mol/l for wild-type
C89A/C186A
-
mutant is properly folded with well-defined tertiary structures
C89A/C186A
-
no significant change in conformation. Decrease in stability and in dissociation constants for 8-anilino-1-naphthalenesulfonic acid. Urea-induced unfolding at 2.625 mol/l compared with 5.75 mol/l for wild-type
additional information
chimeric protein construct carrying the mouse amino-terminal portion from D25 to L84, and zebrafish carboxyl-terminal portion from K79 to A184, shows weak enzymic activity
additional information
-
chimeric protein construct carrying the mouse amino-terminal portion from D25 to L84, and zebrafish carboxyl-terminal portion from K79 to A184, shows weak enzymic activity
additional information
-
transgenic expression of hematopoitic prostaglandin synthase in ApcMin/+ mice have 80% fewer intestinal adenomas
additional information
-
apoptosis induced by chemotherapeutics paclitaxel, cisplatin and 5-fluorouracil is prevented by siRNA targeting lipocalin-type prostaglandin synthase-D
additional information
knockdown of the enzyme expression by siRNA in SH-SY5Y cells, two different siRNAs
additional information
-
chimeric protein construct carrying the mouse amino-terminal portion from D25 to L84, and zebrafish carboxyl-terminal portion from K79 to A184, shows weak enzymic activity
additional information
-
disruption of gene for hematopoietic prostaglandin synthase in ApcMin/+ mice bearing a defect in the adenomatous polyposis coli gene which leads to development of many adenomas leads to 50% more intestinal adenomas compared with controls. Tumour size is not affected
additional information
-
enzyme knockout animals and transgenic animals. Knockout mice display a more severe inflammatory response that fails to resolve, whereas transgenic mice have little detectable inflammation. Lymphocytes isolated from inguinal lymph nodes of knockout mice show hyperproliferation and increased IL-2 synthesis effects that are rescued by 15-deoxy-DELTA12,14-prostaglandin J2, but not prostaglandin D2
additional information
-
transgenic mice overexpressing the enzyme improve clearance of Pseudomonas from the lung compared with nontransgenic mice, as does intratracheal instillation of prostaglandin D2. Enzyme knock-out mice show impaired ability to remove Pseudomonas from the lung
additional information
-
adipocytes from lipocalin-type prostaglandin synthase-D knockout mice are significantly less sensitive to insulin-stimulated glucose transport than wild-type
additional information
-
generation of double knock out mice lacking lipocalin prostaglandin D synthase and PPARgamma2
additional information
-
generation of double knock out mice lacking lipocalin prostaglandin D synthase and PPARgamma2
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH STABILITY
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
60
purified recombinant enzyme, sodium phosphate, pH 7.0, containing 5% v/v ethanol, stable up to
65 - 90
purified recombinant enzyme, thermal unfolding in the absence and presence of small lipophilic ligands, two-state unfolding transition, overview
additional information
thermal unfolding is completely reversible at pH 4.0, with the presence of an intermediate state I between the native state N and the unfolded state U. Transition temperatures of the N-I and I-U transitions are 48.2 and 60.3°C, respectively. In the intermediate state, the main chain retains its characteristic beta-sheet structure without side.chain interactions
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
by ammonium sulfate precipitation, and on a GSH Sepharose 4B and a Superdex 75 pg column
DEAE-Sepharose column chromatography and Superdex 200 gel filtration
glutathione Sepharose column chromatography and Superdex 75 gel filtration
GST-Prep column chromatography
Ni-NTA agarose column chromatography and glutathione-Sepharose column chromatography
optimized expression protocol for recombinant enzyme in Escherichia coli and purification protocol yielding large amounts of isotopically labeled enzyme
-
recombinant C-terminally His6-tagged enzyme from Escherichia coli strain Rosetta BL21(DE3) by nickel affinity chromatography and gel filtration
recombinant GST-tagged truncated enzyme mutant C65A/C167A from Escherichia coli strain BL21(DE3) by glutathione affinity chromatography, gel filtration, and dialysis
recombinant GST-tagged wild-type and mutant enzymes from Escherichia coli strain BL21 (DE3) by glutathione affinity chromatography, gel filtration, and dialysis
recombinant PGDS
the DELTA1-24_C65A L-PGDS mutant is purified on a glutathione-Sepharose 4B column and incubated with thrombin to release the L-PGDS, the protein is further purified by gel filtration
two-step purification method using cerebrospinal fluid
Ni-NTA agarose column chromatography and glutathione-Sepharose column chromatography
-
Ni-NTA agarose column chromatography and glutathione-Sepharose column chromatography
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
expressed in Escherichia coli BL21(DE3) cells
expressed in Escherichia coli C41(DE3) cells
expression in Escherichia coli
expression of C-terminally His6-tagged enzyme in Escherichia coli strain Rosetta BL21(DE3)
expression of cDNA in Escherichia coli
expression of GST-tagged enzyme mutant C65A/C167A, with truncated N-terminal 22-amino acid residues corresponding to the putative secretion signal peptide, in Escherichia coli strain BL21(DE3)
expression of wild-type and mutant enzymes in Escherichia coli strain BL21 (DE3)
expression of wild-type and mutant enzymes in Escherichia coli strain BL21(DE3)
into the vectors pUB6/V5-His and pIRESneo, cDNA of positions 76-648 is cloned into the vector pGEM-T Easy
-
the coding region of human L-PGDS is sub-cloned into pCR-Script Amp SK+ vector
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
expression levels of L-PGDS mRNA and protein are significantly increased after 14 days of hypoxia
-
L-PGDS, but not H-PGDS, is induced on fibroblasts close to infiltrating cells in the Helicobacter pylori-infected gastric mucosa
-
mice lacking PPARgamma2 have elevated levels of lipocalin prostaglandin D synthase expression in brown adipose tissue and subcutaneous white adipose tissue
oral pretreatment with the inhibitor EDJ300520 prevents the lipopolysaccharide-induced PGD2 increase in plasma and lungs
-
the level of L-PGDS mRNA expression is increased 20fold in ulcerative colitis and increases with disease activity
the synthesis of PGD2 is increased in plasma and lungs in response to systemic lipopolysaccharide injection
-
mice lacking PPARgamma2 have elevated levels of lipocalin prostaglandin D synthase expression in brown adipose tissue and subcutaneous white adipose tissue
-
mice lacking PPARgamma2 have elevated levels of lipocalin prostaglandin D synthase expression in brown adipose tissue and subcutaneous white adipose tissue
-
-
the level of L-PGDS mRNA expression is increased 20fold in ulcerative colitis and increases with disease activity
-
the level of L-PGDS mRNA expression is increased 20fold in ulcerative colitis and increases with disease activity
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
RENATURED/Commentary
ORGANISM
UNIPROT
LITERATURE
complete recovery of activity after denaturation with 2 M guanidinium hydrochloride or 4 M urea
thermal unfolding is completely reversible at pH 4.0. Differential scanning calorimetry data show no concentration dependency. Presence of an intermediate state I between the native state N and the unfolded state U. Transition temperatures of the N-I and I-U transitions are 48.2 and 60.3°C, respectively. In the intermediate state, the main chain retains its characteristic beta-sheet structure without side.chain interactions
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
analysis
medicine
nutrition
-
prostaglandin D2 stimulates food intake after intracerebroventricular administration in mice. Central administration of an antagonist or antisense oligodeoxynucleotide for the DP1 receptor remarkably decreases food intake, body weight and fat mass. Hypothalamic mRNA levels of lipocalin-type PGD synthase are up-regulated after fasting
synthesis
-
optimized expression protocol for recombinant enzyme in Escherichia coli and purification protocol yielding large amounts of isotopically labeled enzyme
analysis
-
particle concentration fluorescence immunoassay for prostaglandin D synthase is suitable for determining the content of prostaglandin D synthetase in various regions of the rat CNS. The method allows to assay a large number of samples with reasonable sensitivity
analysis
-
PGD synthase is a useful marker for identifying the differentiation stage of human megakaryocytic cells
medicine
-
the enzyme may be a potential marker that may aid in the differential diagnosis of obstructive and non-obstructive azoospermia
medicine
-
enzyme mRNA is up-regulated in mouse model of globoid cell leukodystrophy or Krabbes disease, of Tay-Sachs disease, Sandhoff disease, GM1 gangliosidosis and Niemann-Pick type C1 disease,. Oligodendrocytes of all these mouse models show strong immunoreactivity for enzyme, but not astrocytes or microglia
medicine
-
hematopoietic prostaglandin D2 synthase derived prostaglandins may protect against inflammatory diseases, where T-lymphocytes play a pathogenic role, as in rheumatoid arthritis, atopic eczema, and chronic rejection
medicine
-
hematopoitic prostaglandin synthase controls an inhibitory effect on intestinal tumours
medicine
-
hematopoitic prostaglandin synthase controls an inhibitory effect on intestinal tumours
medicine
-
lipocalin-type prostaglandin D synthase may have the ability to improve progressive motility of sperm and, in seminal plasma and on sperm surface, may impact male fertility in the female reproductive tract
medicine
-
prostaglandin synthase and testicular factor SOX9 are expressed at both RNA and protein levels in different types of ovarian tumors, while treatment of these cells with prostaglandin D2 can inhibit their growth and induce apoptosis
medicine
-
the lipocalin-type prostaglandin D synthase, prostaglandin D2, and prostaglandin D receptor system plays a pivotal role in the regulation of physiological sleep
medicine
-
transgenic mice overexpressing the enzyme improve clearance of Pseudomonas from the lung compared with nontransgenic mice, as does intratracheal instillation of prostaglandin D2. Enzyme knock-out mice show impaired ability to remove Pseudomonas from the lung. Potential therapeutic use of enzyme or prostaglandin D2 against Pseudomonas pneumoniae
medicine
-
apoptosis induced by chemotherapeutics paclitaxel, cisplatin and 5-fluorouracil is prevented by siRNA targeting lipocalin-type prostaglandin synthase-D
medicine
-
both hematopoietic- and lipocalin-type prostaglandin-D synthase are present in cartilage from healthy donors as well as from patients with osteoarthritits. Level of lipocalin-type prostaglandin-D synthase is more than 20fold higher than hematopoietic-type enzyme. Levels of lipocalin-type prostaglandin-D synthase mRNA and protein are increased in cartilage from aptients with osteoarthritis. Treatment of chondrocytes with IL-1beta upregulates lipocalin-type prostaglandin-D synthase mRNA and protein expressions as well as prostaglandin D2 production in a dose- and time-dependent manner. The upregulation of lipocalin-type prostaglandin-D synthase by IL-1beta is blocked by the translational inhibitor cycloheximide. Specific inhibitors of the MAPK p38 and c-jun N-terminal kinase and of the NF-kappaB and Notch signalling pathways suppress IL-1beta-induced upregulation of lipocalin-type prostaglandin-D synthase expression. An inhibitor of the extracellular signal-regulated kinase ERK/MAPK demonstrates no significant influence. Prostaglandin D2 prevents IL-1beta-induced upregulation of lipocalin-type prostaglandin-D synthase expression
medicine
-
in patients receiving long-term intravenous administration of gentamicin for the treatment of infective endocarditis, systemic clearance of gentamicin is reduced by 10% from the early to late treatment phase, wherease urinary lipocalin-type prostaglandin synthase excretion shows a significant increase. No significant changes are observed for urinary beta2-microglobulin and N-acetyl-beta-D-glucosaminidase concentrations
medicine
-
in patients with acute inflammatory demyelinating polyneuropathy, concentration of prostaglandin-D synthase is significantly increased in cerebrospinal fluid, due to a blood-cerebrospinal fluid barrier dysfunction. The intrathecal synthesis of prostaglandin-D synthase is significantly decreased in these patients. Changes of the ratio of cerebrospinal fluid prostaglandin-D synthase to albumin are only observed in patients with acute inflammatory demyelinating polyneuropathy, but not in Miller Fisher Syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, or multiple sclerosis patients
medicine
-
in patients with HIV infection who have progressive neurocognitive decline over the next 6 months and in patients with a history of intravenal drug use, 3-nitrotyrosine modified proteins are significantly elevated. Among the 13 different proteins with 3-nitrotyrosine modification identified, lipocalin-type prostaglandin-D synthase is the most abundant, and the modification results in loss of enzymatic activity
medicine
-
in patients with stabel coronary artery disease who underwent diagnostic coronary angiography, the most powerful independent predictor of the coronary severity score is the level of lipocalin-type prostaglandin-D synthase
medicine
-
level of seminal plasma lipocalin-type prostaglandin-D synthase is significantly lower in groups with obstruction of the male seminal tract. Men with nonobstructive azoospermia have less homogenity of lipocalin-type prostaglandin-D synthase levels. Lipocalin-type prostaglandin-D synthase can be a potential biomarker for assessing patency in the seminal tract in men with azoospermia. In men with azoospermia and high seminal lipocalin-type prostaglandin-D synthase levels, the diagnosis of nonobstructive azoospermia can be potentially made without biopsy
medicine
orally administered AT-56, i.e. 4-dibenzo [a,d]cyclohepten-5-ylidene-1-[4-(2H-tetrazol-5-yl)-butyl]-piperidine, below 30 mg/kg body weight decreases the prostaglandin D2 production to 40% in the brain of H-PGDS-deficient mice after a stab-wound injury in a dose-dependent manner without affecting the production of prostaglandin E2 and prostaglandin F2alpha, and also suppresses the accumulation of eosinophils and monocytes in the bronco-alveolar lavage fluid from the antigen-induced lung inflammation model of human L-PGDS-transgenic mice
medicine
-
prostaglandin D2 stimulates food intake after intracerebroventricular administration in mice. Central administration of an antagonist or antisense oligodeoxynucleotide for the DP1 receptor remarkably decreases food intake, body weight and fat mass. Hypothalamic mRNA levels of lipocalin-type PGD synthase are up-regulated after fasting
medicine
-
study on the pharmacokinetics of recombinant human lipocalin-type prostaglandin-D synthase in canines. After an intravenous bolus injection, the serum concentration decreases biexponentially with a half-life of the terminal line phase of 0.77 h. L-PGDS is distributed mainly in the blood. Only 10.3% of the administered enzyme is excreted to the urine, suggesting that L-PGDS is actively degraded within the body
medicine
-
based on the observations it is speculated that PGD2 acts as one of the immuno-modulating molecules in gastric mucosa infected with Helicobacter pylori, PGD2 might be involved in the pathophysiology of other gastric diseases, such as gastric ulcers or erosion
medicine
-
dendritic cells in the epidermis and dermis are capable of functioning as an important source of PGD2 in the skin, thereby contributing to or regulating innate and/or acquired immune responses of the skin
medicine
-
induction of L-PGDS expression in the heart as a response to hemodynamic stress
medicine
-
L-PGDS is beneficial for protecting the brain against transient and permanent cerebral ischemia, these results provide a better understanding of the role played by the enzymes that control eicosanoid synthesis and how they can be utilized as potential targets to prevent damage following either acute or potentially chronic neurological disorders
medicine
-
prostaglandin D2 produced by hematopoietic prostaglandin D synthase contributes to lipopolysaccharide-induced fever
medicine
prostaglandin D2 synthesized by the hematopoietic prostaglandin D2 synthase has a pro-inflammatory effect in allergic asthma, regulating many hallmark characteristics of the disease
medicine
-
the results demonstrate that the neuroprotective effects of hematopoietic prostaglandin D synthase in the model are mediated by suppression of activation and infiltration of inflammatory cells
medicine
elevated enzyme levels in the cervicovaginal secretions of women are a potential biomarker for preterm birth
medicine
-
the enzyme is a biomarker for the assessment of cerebrospinal fluid leaks
Select items on the left to see more content.
EXTERNAL LINKS (specific for EC-Number 5.3.99.2)
html completed
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
